z-logo
open-access-imgOpen Access
Impact of microRNA-34a and polymorphism of its target gene CA9 on susceptibility to uterine cervical cancer
Author(s) -
Shun Fa Yang,
Yu Fan Liu,
Chao Cheng,
Wei Yang,
Wea Lung Lin,
JiunnLiang Ko,
Po Hui Wang
Publication year - 2017
Publication title -
oncotarget
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.373
H-Index - 127
ISSN - 1949-2553
DOI - 10.18632/oncotarget.20842
Subject(s) - single nucleotide polymorphism , medicine , cervical cancer , university hospital , gynecology , oncology , cancer , genotype , genetics , biology , gene
The purposes of this study were to associate the genetic polymorphisms in carbonic anhydrase (CA) 9 with uterine cervical cancer and identify the clinical implications. Three single-nucleotide polymorphisms (SNPs), rs2071676 (+201, G/A), rs3829078 (+1081, A/G), and rs1048638 (+1584, C/A), and an 18-base-pair deletion/insertion (376del393) in CA9 were examined. We used the Boyden chamber assay to evaluate the influence of CA9 on the migration of cervical cancers. Tissue microarrays were used to evaluate CAIX immunoreactivity and determine its clinical significance. The results revealed that the CA9 SNP rs1048638 is the only significant polymorphism that increases the risk of cervical cancer in Taiwanese women. We discovered that the CA9 SNP rs1048638 influences the expression of CA9 through the interaction between the 3'-untranslated region (UTR) of exon 11, where the SNP is located, and miR-34a, and influences the migration of cervical cancer cells. Moreover, we demonstrated that CAIX immunoreactivity is related to the occurrence of cervical cancer, and elevated CAIX immunoreactivity is associated with a more advanced stage. In conclusion, the finding that the CA9 SNP rs1048638 exerts its action through duplexes of the miR-34a and CA9 3'-UTRs and plays a vital role in cervical cancer in Taiwanese women may be applicable to translational medicine.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here